- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
Stamford Hospital and Dana-Farber/Brigham and Women’s Cancer Center Announce Expanded Collaboration
November 10, 2020
Article
Dana-Farber/Brigham and Women’s Cancer Center formally announced an exclusive, expanded collaboration to increase access to DF/BWCC experts and resources for patients at Stamford Health’s Carl & Dorothy Bennett Cancer Center.
Dr. Beltran on the Significance of Genomic Sequencing in Prostate Cancer
November 09, 2020
Video
Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.
Dr. Krop on the Role of Neratinib as Extended Adjuvant Therapy in HR+/HER2+ Breast Cancer
November 09, 2020
Video
Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.
Dr. Beltran on the Need to Identify Non–AR Targets in Prostate Cancer
November 03, 2020
Video
Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.
Dr. Davids on the Future of CAR T-Cell Therapy in CLL
October 27, 2020
Video
Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.
Dr. Jacobson on the Significance of CD19-Targeted CAR T-Cell Therapy in B-Cell Malignancies
October 27, 2020
Video
Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.
Adagrasib Shows Early Activity in KRAS G12C+ NSCLC, CRC, and Other Solid Tumors
October 26, 2020
Article
Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.
Dr. Jacobson on FDA Approval of Brexucabtagene Autoleucel in Relapsed/Refractory MCL
October 26, 2020
Video
Caron Jacobson, MD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.
Dr. Tolaney on Escalating Versus De-Escalating Therapies in HER2+ Breast Cancer
October 23, 2020
Video
Sara M. Tolaney, MD, MPH, discusses escalating versus de-escalating therapies in HER2-positive breast cancer.
Dr. Tolaney on Data With Trastuzumab Deruxtecan in HER2+ Breast Cancer Brain Metastases
October 22, 2020
Video
Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.
Tolaney Touches on HER2+ -Low Breast Cancer Testing, Possibilities, and Challenges
October 16, 2020
Article
Sara M. Tolaney, MD, MPH, discusses the challenges in treating patients with heterogenous HER2 expression and what treatments could potentially improve outcomes for this subgroup.
Dr. Davids on Investigational Doublets and Triplets in CLL
October 15, 2020
Video
Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.
Novel Approaches Lead the Charge Away from Chemoimmunotherapy in CLL
October 14, 2020
Article
Matthew S. Davids, MD, MMSc, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia and ongoing research in the space.
Dr. Davids on Selecting Between Continuous and Time-Limited Therapy in CLL
October 13, 2020
Video
Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.
Dr. Bakouny on the Rate of Disease Progression in Sarcomatoid Carcinoma
October 12, 2020
Video
Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.
Dr. Davids on Factors to Inform Treatment Selection in CLL
October 09, 2020
Video
Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.
Dr. Lin on Treatment Challenges in HER2+ Breast Cancer and Brain Metastases
October 08, 2020
Video
Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.
Choueiri Highlights Efficacy of Cabozantinib/Nivolumab in RCC, Next Steps for Research
October 07, 2020
Article
Toni Choueiri, MD, discusses the CheckMate-9ER trial, the next steps for nivolumab/cabozantinib, and other cabozantinib regimens under exploration.
Neoadjuvant Nivolumab/Chemo Combo Significantly Improves pCR in Resectable NSCLC
October 07, 2020
Article
The combination of nivolumab plus chemotherapy resulted in a statistically significant improvement in pathologic complete response when used as neoadjuvant treatment in patients with resectable non–small cell lung cancer, meeting the primary end point of the phase 3 CheckMate-816 trial.
Dr. Davids on the Use of Chemoimmunotherapy in CLL
October 06, 2020
Video
Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.